MarketWatch on MSN54m
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
devdiscourse34m
Eli Lilly Slashes Prices on Weight-Loss Drug to Boost Demand
Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...
Hims & Hers flags possible halt to compounded weight-loss drug sales; shares slump
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
pharmaphorum34m
Lilly launches discounted high-strength Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
pharmaphorum37m
Lilly launches discounted Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Eli Lilly rolls out new Zepbound vial versions on LillyDirect
Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...